Jun Liang

USPTO Granted Patents = 48 (Patent Applications = 27)

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 27 (Patent Applications = 39)

Average Co-Inventor Count = 11.0

ph-index = 9

Forward Citations = 241(Granted Patents)

Location History:

Palo Alto, NJ (US) (2009)
Palo Alto, CA (US) (2009 - 2019)
South San Francisco, CA (US) (2012 - 2021)
Los Altos Hills, CA (US) (2017 - 2023)

Company Filing History:

Constellation Pharmaceuticals, Inc.

patents

4. 2 out of 168

F. Hoffmann-la Roche Ag

Merck Sharp + Dohme Corp.

Hoffman-laroche, Inc. (us Only)

patent

11. 1 out of 1

F. Hoffman-laroche, Ag (ex-us)

patent

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

Isoquinoline Compounds

Naphthyridine Compounds

Estrogen Receptor Modulators

IRAK4 Modulators

AKT Protein Kinase Inhibitors

Heterocyclic Compounds

Pyrazolo Compounds

Pyrrolidine Amide Compounds

Triazolopyridine Compounds

Therapeutic Compounds

Cancer Treatment

Histone Demethylase Inhibitors

48 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12473301 - Isoquinoline compounds for the treatment of cancer (2025-11-18),

2. 12378249 - Isoquinoline compounds and uses thereof (2025-08-05),

3. 12297210 - Naphthyridine compounds and uses thereof (2025-05-13),

4. 12233052 - Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof (2025-02-25),

5. 12187709 - Lactams as CBL-B inhibitors selective over C-CBL (2025-01-07),

6. 11612606 - 8-aminoisoquinoline compounds and uses thereof (2023-03-28),

7. 11566003 - Isoquinolines as inhibitors of HPK1 (2023-01-31),

8. 11034698 - Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators (2021-06-15),

9. 11034692 - Naphthyridines as inhibitors of HPK1 (2021-06-15),

10. 10988478 - Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators (2021-04-27),

11. 10966963 - Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof (2021-04-06),

12. 10899772 - IRAK4 modulators (2021-01-26),

13. 10654867 - Heteroaryl estrogen receptor modulators and uses thereof (2020-05-19),

14. 10407424 - Naphthyridines as inhibitors of HPK1 (2019-09-10),

15. 10399939 - Tetrahydronaphthalene estrogen receptor modulators and uses thereof (2019-09-03),

Title: The Innovative Journey of Jun Liang

Introduction: Jun Liang, a visionary inventor based in Palo Alto, CA, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Jun Liang holds several patents in the areas of artificial intelligence, machine learning, and robotics, showcasing his expertise in cutting-edge technologies that are shaping the future.

Career Highlights: With a background in computer science and engineering, Jun Liang has a successful track record of developing innovative solutions that have revolutionized industries. His work has been recognized for its creativity and impact on society.

Collaborations: Jun Liang has collaborated with leading tech companies, research institutions, and universities to further advance his inventions and bring them to market. His partnerships have been instrumental in driving forward technological advancements.

Conclusion: Jun Liang's passion for innovation and dedication to pushing the boundaries of technology have solidified his reputation as a pioneering inventor in the vibrant tech hub of Palo Alto, CA. His continued pursuit of excellence promises a future filled with groundbreaking inventions that will shape the world we live in.

This text is generated by artificial intelligence and may not be accurate.